Clinical Trial Search

Primary: Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward) — -0.8; -0.8; -1.6; -1.2 frequency of…

Primary: Change in HbA1c From Baseline to Week 26 — -0.26; -0.89; -1.03 Percent — p=<0.001

Primary: Percentage of Participants Achieving Dose Titration Success — 80.60 Percentage of participants

Primary: Immunogenicity, Assessed by the Haemagglutination (HI) Test — 97.2; 89.7; 92.7; 90.5 percentage of participants — p=0.0036

Primary: Immunogenicity of a Single Full (0.5 mL) Dose and a 0.25 mL 2-dose Regimen of Inflexal V, Using the EMA Guideline for the Re-registration of the Seasonal Influenza…

Primary: Percentage of Women With Serious Adverse Events — 0.0 percentage of women

Primary: Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone — -0.01; 0.00 ratio — p=0.121

Primary: Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator — 10.6; 6.2 Months — p=<0.0001

Primary: Incidence Rate of Composite Efficacy Failure From Randomization to Month 12 — 6.7; 24.2; 9.7 Percentage of participants

Primary: Estimated Percentage of Misuse for Non-Therapeutic Reasons — 6.5 Percentage of Participants

Primary: Numeric Index of American College of Rheumatology Response (ACR-N, N Shows the Percent Improvement) — 51.3; 53.8; 58.3 percent change

Primary: Change in HbA1c From Baseline to Week 52 — -1.03; -0.66 Percent — p=<0.05

Primary: Participants Experiencing an Asthma Exacerbation That Requires Systemic Corticosteroid Therapy — 22; 20; 25; 36 participants — p=0.066

Primary: Number of Participants With Peripheral Edema — 5; 9; 2; 0 Participants

Primary: Treatment or "Failure" Defined as Vitrectomy — 12; 17 percentage of participants — p=0.37